LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the MiMedx investigation page on our website www.glancylaw.com/case/mimedx-group-inc-0.
On October 23, 2017, First Analysis published a report alleging that the Company has “excluded (First Analysis) from asking questions on multiple calls while spending substantial time sparring with ‘short sellers’ and filing lawsuits.” Specifically, well-known short-seller Marc Cohodes tweeted that he thinks MiMedx will not make it through their audit and calls on CEO Pete Petit to resign.
On this news, MiMedx fell 11.4%, or $1.58 per share, to close at $12.32 on October 23, 2017.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased MiMedx securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.